ReviewJournal of the European Academy of Dermatology and Venereology : JEADV2026
Dermatology 2.0: Precision medicine for inflammatory skin diseases.
Review in Journal of the European Academy of Dermatology and Venereology : JEADV, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Oral lichenoid lesions in CTLA-4 haploinsufficiency: Targeting IFN-γ-driven mucosal immunopathology.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Reframing molecular superiority in the differential diagnosis of eczema and psoriasis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Molecular differentiation of psoriasis and eczema: Reference standards and benchmarking caveats.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Patient-Reported Experiences in Chronic Dermatological Conditions: Validation of the Romanian PSPSQ 2.0 Within Contemporary Dermatologic Care Pathways.Diagnostics (Basel, Switzerland) · 2026Article
- Bridging theory and practice in model-informed precision dosing of medication in inflammatory skin diseases.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Secukinumab in Refractory Generalized Darier's Disease with a 40-Year Disease Duration: A Case Report.Clinical, cosmetic and investigational dermatology · 2026Article
- Type I interferon in psoriasis: mechanisms and clinical implications.Frontiers in immunology · 2026Review
- Editorial: Exploring innovative therapies for rare inflammatory skin diseases.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Recent advances in immunology and transcriptomics have transformed dermatology, redefining inflammatory skin diseases as distinct molecular entities characterized by dominant immune pathways such as Th17, Th2, Th1, type I interferon (IFN) and myeloid modules. We transcriptionally delineated these immune modules, constructed a reference immune cartography to map patient skin biopsies and developed a digital platform that enables clinicians to analyse individual molecular profiles, facilitating precise diagnosis for clinically overlapping or diagnostically ambiguous dermatoses. Beyond diagnostic utility, this platform supports therapeutic decision-making by aligning each patient's dominant immune module with the most appropriate targeted treatment. Analyses of treatment failures reveal that discordance between therapy and immune module dominance, as well as immune shifts between modules, account for most cases of non-response. Realigning therapy with the patient's molecular profile restores efficacy and enables rational adaptation or repurposing of existing agents. By integrating molecular diagnostics with immune module-guided therapy, this approach establishes a precision medicine framework that optimizes outcomes and advances personalized care for patients with inflammatory skin disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.